Tratamiento conservador de la enfermedad de Peyronie: colchicina versus colchicina más vitamina E

Cortés-González, J.R.; Glina, Sidney

doi:10.1016/j.acuro.2010.03.009

Cited by 9 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, there were only 45 patients in this trial and there was no placebo arm. However, a subsequent retrospective study of 100 men exposed no statistically significant differences in efficacy for pain relief, penile curvature, or plaque size between colchicine and colchicine combined with vitamin E ( 17 ).…”

Section: Colchicinementioning

confidence: 99%

Oral therapy for Peyronie’s disease, does it work?

Barrett-Harlow¹,

Wang²

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

Peyronie’s disease (PD) is a localized, wound-healing, connective tissue disorder of the penis characterized by scarring of the tunica albuginea. This fibrous inelastic scar leads to penile pain, penile deformity and erectile dysfunction (ED), and a difficulty performing coitus. Over the past several decades, a myriad of oral agents for the treatment of PD have been studied and suggested. While the gold standard of care remains surgical therapy, many physicians continue to prescribe oral and intralesional injections for treatment during the acute phase of the disease. This article seeks to summarize the different oral therapy agents for PD and the research associated with each medication. While the American Urological Association has not recommended most of the mentioned medications for the treatment of PD, two newer therapies have shown success and have the potential of becoming baseline treatments for the acute phase of PD.

show abstract

Section: Colchicinementioning

confidence: 99%

Oral therapy for Peyronie’s disease, does it work?

Barrett-Harlow¹,

Wang²

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…Colchicine is an anti-inflammatory medication that has been widely used orally in rheumatologic diseases, such as gout ( 10 , 11 ). More recently, it has been used in Peyronie's disease due to its capacity to inhibit mitoses of collagen-producing cells and to inhibit the fibroblast growth factor ( 10 , 12 , 13 ). The use of colchicine injected directly into the penile plaque during the acute phase of the disease could have greater efficacy than oral use, due to higher levels of the drug in the tissue.…”

Section: Introductionmentioning

confidence: 99%

A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study

et al. 2016

Self Cite

View full text Add to dashboard Cite

Objectives:To compare the response to tiocolchicine and verapamil injection in the plaque of patients with Peyronie's disease.Materials and Methods:Prospective, single-blind, randomized study, selecting patients who have presented Peyronie's disease for less than 18 months. Thiocolchicine 4mg or verapamil 5mg were given in 7 injections (once a week). Patients who had received any treatment for Peyronie's disease in the past three months were excluded. The parameters used were the International Index of Erectile Function (IIEF-5) score, analysis of the curvature on pharmaco-induced erections and size of the plaque by ultrasonography.Results:Twenty-five patients were randomized, 13 received thiocolchicine and 12 were treated with verapamil. Both groups were statistically similar. The mean curvature was 46.7° and 36.2° before and after thiocolchicine, respectively (p=0.019) and 50.4° and 42.08° before and after verapamil, respectively (p=0.012). The curvature improved in 69% of patients treated with thiocolchicine and in 66% of those who received verapamil. Regarding sexual function, there was an increase in the IIEF-5 from 16.69 to 20.85 (p=0.23) in the thiocolchicine group. In the verapamil group the IIEF-5 score dropped from 17.50 to 16.25 (p=0.58). In the thiocolchicine group, the plaque was reduced in 61% of patients. In the verapamil group, 8% presented decreased plaque size. No adverse event was associated to thiocolchicine.Conclusion:The use of thiocolchicine in Peyronie's disease demonstrated improvement on penile curvature and reduction in plaque size. Thiocolchicine presented similar results to verapamil in curvature assessment. No significant side effects were observed with the use of tiocolchicine.

show abstract

Non‐surgical therapy for Peyronie's disease

Rees¹,

Dawson²

2016

Male Sexual Dysfunction

View full text Add to dashboard Cite

Tratamiento conservador de la enfermedad de Peyronie: colchicina versus colchicina más vitamina E

Cited by 9 publications

References 18 publications

Oral therapy for Peyronie’s disease, does it work?

Oral therapy for Peyronie’s disease, does it work?

A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study

Non‐surgical therapy for Peyronie's disease

Contact Info

Product

Resources

About